- Canaccord starts recently public Enzymotec (ENZY +1%) at Buy.
- Analyst Scott Van Winkle says the company "is well positioned to drive sustained growth in the highly attractive nutrition market, translating into strong sales, margin, and earnings momentum."
- Price target is $24, representing a 35% upside from Monday's close.
- Also picking up coverage is Wedbush, where analyst Rommel Dionisio starts the shares at Outperform with a $21 price target. "With its proprietary technology in lipids and expanding global distribution platform, ENZY will continue to gain market share within three fast-growing industry segments of nutritional foods and supplements: krill oil; infant nutrition; and medical foods," Dionisio says.
- Wedbush note is here